Gynecologic oncology最新文献

{"title":"Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer","authors":"Wenjie Tang ,&nbsp;Lu Wang ,&nbsp;Xiaolin Li ,&nbsp;Xiaohui Yan ,&nbsp;Qiufen Guo ,&nbsp;Qian Wu ,&nbsp;Chunhui Cui ,&nbsp;Bowen Liu ,&nbsp;Jianbo Zhang ,&nbsp;Lu Zhang ,&nbsp;Xueliang Zhang ,&nbsp;Dapeng Li ,&nbsp;Peng Xie","doi":"10.1016/j.ygyno.2025.12.007","DOIUrl":"10.1016/j.ygyno.2025.12.007","url":null,"abstract":"<div><h3>Objective</h3><div>Although widely used for immune checkpoint inhibitors (ICIs) therapy patient selection, programmed death-ligand 1 (PD-L1) remains an imperfect biomarker for such selection. We explored the impact of radiotherapy (RT) on PD-L1 and the tumor microenvironment (TME) and delved into the mechanisms underlying this effect in cervical cancer.</div></div><div><h3>Methods</h3><div>Patients with treatment-naïve cervical cancer who underwent RT between March 2021 and October 2022 were included. Cancer tissue samples were collected during RT. PD-L1 expression was evaluated by immunohistochemical staining. Lymphocytes in the TME were detected by multiplex immunofluorescence (mIF). SiHa, CaSki, U14, and TC-1 cells verified the in vitro findings using western blot analysis.</div></div><div><h3>Results</h3><div>Among the 40 cases, although the expression changed constantly, PD-L1 was significantly upregulated in most patients exposed to doses of 10–14 and 18–22 Gy; this radiation-induced acquired PD-L1 expression was consistently observed regardless of patients' baseline PD-L1 status or concurrent chemotherapy. In vitro experiments confirmed increased PD-L1 post-RT. RNA sequencing revealed NF-κB signaling pathway enrichment in the CD274-elevated group. Western blotting indicated significant p-P65 and p-IKKα/β increases post-irradiation; PD-L1 decreased with NF-κB activation inhibitors. mIF demonstrated increased CD8⁺ T cell and macrophage infiltration into tumor nests (<em>P</em> = 0.0496; <em>P</em> = 0.0017) and tumor stroma (<em>P</em> = 0.0049), with overall increased TME infiltration (<em>P</em> = 0.0139; <em>P</em> = 0.0321).</div></div><div><h3>Conclusion</h3><div>RT induces PD-L1 expression and enhances CD8⁺ T cell and macrophage infiltration into the TME of patients with cervical cancer. Therefore, it may establish an immunologically favorable context for synergistic action with subsequent immunotherapy.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 17-26"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining PARP inhibitor use in HGSOC: The role of HRD testing in clinical decision making","authors":"Radha Maradiya ,&nbsp;Soufian El Hallani ,&nbsp;Martin Koebel ,&nbsp;Cheng-Han Lee ,&nbsp;Christa Aubrey","doi":"10.1016/j.ygyno.2026.01.215","DOIUrl":"10.1016/j.ygyno.2026.01.215","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages S21-S22"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in time from diagnosis to initiation of chemoradiation in cervical cancer in the United States: A national cancer database analysis","authors":"Ting-Tai Yen ,&nbsp;Tina Yi Jin Hsieh ,&nbsp;Gin Yi Lee ,&nbsp;Alexander Melamed ,&nbsp;Joseph Dottino","doi":"10.1016/j.ygyno.2026.01.231","DOIUrl":"10.1016/j.ygyno.2026.01.231","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages S31-S32"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating birth outcomes in early cervical cancer after trachelectomy versus hysterectomy: A cost-effective analysis","authors":"Abigail Barger,&nbsp;Allison Walker,&nbsp;Sarah Huepenbecker","doi":"10.1016/j.ygyno.2026.01.198","DOIUrl":"10.1016/j.ygyno.2026.01.198","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Page S11"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implantable ports in ovarian cancer: Patient experiences and the need for shared decision-making","authors":"Sarah Boyle ,&nbsp;Deanna Teoh ,&nbsp;Deborah Binder ,&nbsp;Katherine Brown ,&nbsp;Emma Kelly ,&nbsp;Helen Parsons ,&nbsp;Rachel Vogel","doi":"10.1016/j.ygyno.2026.01.200","DOIUrl":"10.1016/j.ygyno.2026.01.200","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages S12-S13"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the prognostic impact of the molecular subclassification of the FIGO 2023 endometrial cancer staging system in early-stage disease","authors":"Jenna Zimmerman ,&nbsp;Megan Snyder ,&nbsp;Meghan St John ,&nbsp;Angeles Alvarez Secord ,&nbsp;Jason Wright ,&nbsp;Michelle Lightfoot ,&nbsp;Victoria Bae-Jump ,&nbsp;Mary Mullen ,&nbsp;Aine Clements ,&nbsp;Yue Yin ,&nbsp;Thomas Krivak ,&nbsp;Eirwen Miller ,&nbsp;Zachary Horne ,&nbsp;John Nakayama ,&nbsp;Christopher Morse ,&nbsp;Alyssa Wield ,&nbsp;Sarah Crafton","doi":"10.1016/j.ygyno.2026.01.232","DOIUrl":"10.1016/j.ygyno.2026.01.232","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages S32-S33"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in access to gynecologic oncology visits among elderly patients with gynecologic malignancies","authors":"Clare Cutri-French ,&nbsp;Daniel H. Saris ,&nbsp;Sebastian Spataro Solorzano ,&nbsp;Xingmei Wang ,&nbsp;Colleen M. Brensinger ,&nbsp;Emily M. Ko","doi":"10.1016/j.ygyno.2026.01.010","DOIUrl":"10.1016/j.ygyno.2026.01.010","url":null,"abstract":"<div><h3>Objectives</h3><div>Despite evidence-based recommendations from SGO, ACOG, and NCCN, not all patients with gynecologic malignancies undergo consultation and management by a gynecologic oncologist. We aim to define the proportion of elderly patients with gynecologic cancers who had at least one visit with a gynecologic oncologist and evaluate for disparities in access to specialist care.</div></div><div><h3>Methods</h3><div>This is a retrospective cohort study of women with staged ovarian, uterine, and cervical cancer between 2000 and 2019 in the SEER Medicare database. Specialist visits were captured using Medicare Part B insurance claims. Descriptive statistics, <em>t</em>-tests, chi-squared tests, and univariate logistic regression were used to assess clinical and socioeconomic factors associated with in-person visits.</div></div><div><h3>Results</h3><div>15,249 ovarian, 27,586 uterine, and 2647 cervical cancer patients were included in this study. There was an increase in the proportion of patients who saw gynecologic oncologists over time. Overall, 54.35% of ovarian, 61.49% of uterine, and 62.14% of cervical cancer patients saw a gynecologic oncologist for at least one visit. Those who were younger, living in census tracks with higher median income, and living in the Northeast were more likely to see a gynecologic oncologist. Visit access also varied by stage. Black and Hispanic patients with uterine cancer were more likely to see a gynecologic oncologist.</div></div><div><h3>Conclusions</h3><div>Less than two thirds of elderly patients with newly diagnosed gynecologic malignancies had a visit with a gynecologic oncologist. There were differences in access based on age, stage, geographic region, census track-based median income, and year of diagnosis in all subgroups.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 63-69"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors","authors":"Allison L. Brodsky ,&nbsp;Elio Tahan ,&nbsp;Joseph Celestino ,&nbsp;Ximing Tang ,&nbsp;Maria G. Raso ,&nbsp;Sherita Meyer-Gauen ,&nbsp;Alexandra Bercow ,&nbsp;Barrett Lawson ,&nbsp;R. Tyler Hillman","doi":"10.1016/j.ygyno.2026.01.234","DOIUrl":"10.1016/j.ygyno.2026.01.234","url":null,"abstract":"<div><h3>Objective</h3><div>The purpose of this study is to determine antibody-drug conjugate (ADC) target antigen expression in ovarian sex cord stromal tumors (SCSTs).</div></div><div><h3>Methods</h3><div>This was a retrospective, single-institution study examining SCSTs for immunohistochemical (IHC) expression of antigens targeted by five FDA-approved ADCs (TROP-2, HER2, folate receptor alpha, nectin-4, and tissue factor) plus expression of delta-like ligand 3 (DLL3), the target of tarlatamab-dlle, a bispecific T-cell engager. Demographic and clinical information were abstracted from medical records. Differences in H-scores were evaluated using the Wilcoxon rank-sum tests and correlation between variables was assessed using Spearman's rank correlation coefficient.</div></div><div><h3>Results</h3><div>Thirty-two SCST samples from thirty individual patients were included. The most common diagnosis was adult type granulosa cell tumor. Minimal to no staining was observed for the antigens TROP-2, HER2, folate receptor alpha, nectin-4, and DLL3. Frequent staining for tissue factor was observed in adult GCTs with a median H-score of 49.6 (interquartile range: 1.3–122.8) and 72% had ≥1% expression of tissue factor. A modest positive correlation between H-score and estrogen receptor positivity was noted (Spearman's rho = 0.49, <em>p</em> = 0.06). The tissue factor H-score for the single juvenile GCT was 43.2 and for the two Sertoli Leydig tumors, H-scores were 1 and 10.2.</div></div><div><h3>Conclusion</h3><div>The pervasive absence of HER2, folate receptor alpha, DLL3, TROP-2, and nectin-4 expression in SCSTs suggests ADCs targeting these antigens may be of limited clinical benefit. The design of clinical trials investigating the use of tissue factor-targeting ADCs for the treatment of adult GCTs warrants future consideration.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 99-104"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative radiotherapy in the management of recurrent granulosa cell tumor","authors":"Elio Tahan,&nbsp;Pryia Bhosale,&nbsp;Charlotte Sun,&nbsp;Anil Sood,&nbsp;Lois Ramondetta,&nbsp;David Gershenson,&nbsp;Pamela Soliman,&nbsp;Lilie Lin,&nbsp;R. Tyler Hillman,&nbsp;Alexandra Bercow","doi":"10.1016/j.ygyno.2026.01.225","DOIUrl":"10.1016/j.ygyno.2026.01.225","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages S27-S28"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Underfunded but overperforming: Disparities in funding and publication for gynecologic cancer research","authors":"Michael Richardson ,&nbsp;Anne Gallivan ,&nbsp;Lily Zello ,&nbsp;Chelsea Stewart ,&nbsp;Miles Morrow ,&nbsp;Daniel Kapp ,&nbsp;John Chan ,&nbsp;Melissa Herbst ,&nbsp;Dana Chase","doi":"10.1016/j.ygyno.2026.01.189","DOIUrl":"10.1016/j.ygyno.2026.01.189","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages S3-S4"},"PeriodicalIF":4.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146185006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}